This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
With reference to the release 20 January and the release 12 January and the
offer document for offer to shareholders in Bionor Immuno AS (the "Offer"),
Nutri Pharma ASA ("Nutri Pharma" or the "Company") announces that it has
received acceptances for 97,39% of the shares in Bionor Immuno AS, including
acceptances received after the end of the offer period. This implies that an
important condition under the offer so far is deemed satisfied. Based on the
high level of support from the shareholders in Bionor Immuno AS, and to satisfy
a condition set out in the Offer, the Company intends to move forward to secure
financing. The Company contemplates a private placement of shares from minimum
NOK 50 million to NOK 100 million with minimum subscription amount exceeding EUR
50,000; where the price will be set through a book building process.
Subscription period is currently planned to start 25th January and close 29th
January at 17:30, but may close earlier. Pareto Securities AS will be Lead
Manager and book runner and Orion Securities will be Co-manager. Issuance of
the shares in the private placement will be subject to necessary corporate
resolutions. Completion of the Offer is still subject to the conditions referred
to in the offer, including completion of a private placement of minimum NOK 50
million.
FOR FURTHER INFORMATION:
Trond Syvertsen, CEO +47 23 01 09 60 / + 47 91 72 14 57
[HUG#1375564]
: Brokerage
CFD-Handel
